F4 FundFund
TeamPortfolioRaiseChampionsEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investorsSimilar Firms
Warm Fund

Blue Venture Fund

blueventurefund.com · Chicago, IL

“Back innovative healthcare companies that drive better outcomes and superior value for patients, while leveraging the Blue Cross Blue Shield network's 115 million covered lives to help portfolio companies commercialize and land Blue Plan contracts.”

$1M – $20M
Check Size
Leads & Follows
Lead Tendency
$800M
AUM
01Investment Thesis

Back innovative healthcare companies that drive better outcomes and superior value for patients, while leveraging the Blue Cross Blue Shield network's 115 million covered lives to help portfolio companies commercialize and land Blue Plan contracts.

Exclusion Criteria

Not suited to consumer-only or non-healthcare business models that don't create clear strategic value for Blue Plan payer partners.

02Investment Team
JB
John Banta
President & Managing Director
MD
Matt Downs
Managing Director
CZ
Chris Zock
Managing Director
JC
Jeff Carroll
Managing Director
TH
Tom Hawes
Managing Director
KM
Kelsey Maguire
Managing Director
DP
Dan Phillips
Managing Director
ES
Emir Sandhu
Managing Director
MB
Mark Bartlett
Venture Partner
RA
Richard Antwi-Boasiako
Vice President
KC
Kelly Carlquist
Vice President
AH
Amanda Harlan
Vice President
LM
Liam McDonald
Vice President
BC
Bryna Coyle
Associate
RL
Ryan Lynch
Associate
NT
Noah Trapp
Associate
JS
Jessica Scheets
Vice President, Operations
KM
Kamie Marsillo
Chief of Staff
03F4 Research Brief

Blue Venture Fund Research

Investment Thesis

Blue Venture Fund (BVF) is the collaborative corporate venture capital vehicle of the Blue Cross Blue Shield (BCBS) system, formed in 2008 by participating Blue Plans, the BCBS Association, and investment manager Sandbox Industries. Its mandate is explicitly strategic rather than purely financial: back innovative healthcare companies that drive better outcomes and superior value for patients while advancing the priorities of its Blue Plan owners. The fund leverages the Blue ecosystem's scale (115 million covered lives across 32 participating Blue Plans, roughly 1 in 3 insured Americans) to help portfolio companies commercialize and land contracts with Blue Plans as customers, not just as capital sources.

Sector Focus

BVF organizes its thesis around three pillars of the healthcare ecosystem: Healthcare Technology (health plan experience and operations), Healthcare Services (care delivery redesign and member experience), and Clinical Sciences (improving medical care and clinical decision-making). In practice this spans virtual care and behavioral health, prior authorization and utilization management AI, value-based care enablement, diagnostics, pharmacy and drug pricing, and payer/provider infrastructure software.

Stage Focus

The fund describes itself as stage-agnostic, investing from seed (companies with "an idea and a slide deck") through growth and buyout. In practice the bulk of visible activity clusters around Series A and Series B healthcare technology and services rounds, with occasional later-stage participation in scaled portfolio companies.

Check Size

Publicly reported equity checks range from roughly $1M to $20M, consistent with a fund that both leads early rounds and participates alongside other institutional and strategic investors in larger syndicates.

Lead Tendency

Mixed. BVF has led or co-led rounds (e.g., Humata Health's $25M raise, Onc.AI's $6M round co-led with Accomplice) and also participates as a strategic follower in larger syndicates (e.g., Big Health's $23.7M round led by .406 Ventures and AlleyCorp in February 2026).

Recent Activity

BVF remains actively deploying. Recent disclosed investments include Big Health (digital CBT for insomnia/anxiety, February 2026), Nest Health (Medicaid-focused in-home family primary care, Series A initially announced August 2025 and closed above $22.5M by November 2025), and Humata Health (AI-enabled prior authorization, $25M round, June 2024). The fund has made 80+ investments and recorded 37 exits as of year-end 2024, spanning four fund vintages totaling over $800M in committed capital from 36 BCBS entities.

Portfolio Highlights

Active portfolio spans well-known digital health names including HealthEdge, Rula Health, Somatus, CirrusMD, Prove, Lumeris, Solera Health, and Exai Bio. Notable historical exits include Change Healthcare, Phreesia (public), naviHealth, CareCentrix, HeartFlow, AbleTo, and Verata Health, reflecting a long track record of building and exiting healthcare infrastructure and services companies, several through strategic acquisition by payers, health systems, and larger healthcare technology platforms.

Team

BVF is led by John Banta (President & Managing Director of the Blue Venture Funds and President of the fund's General Partner), supported by a bench of Managing Directors including Matt Downs, Chris Zock, Jeff Carroll, Dr. Tom Hawes, Kelsey Maguire, Dan Phillips, and Dr. Emir Sandhu. The investment team includes Venture Partner Mark Bartlett and Vice Presidents Richard Antwi-Boasiako, Kelly Carlquist, Amanda Harlan, and Liam McDonald, plus Associates Bryna Coyle, Ryan Lynch, and Noah Trapp. Governance includes Board Chairs drawn from senior finance and strategy executives at individual Blue Plans (Louisiana, Independence Blue Cross, Minnesota, North Carolina), reflecting the fund's unique multi-Plan ownership structure.

Decision Process

Investment decisions run through Advisory Groups composed of representatives from different disciplines across the payer and provider Blue Plan network, who review opportunities and provide structured feedback before and after investment. This gives BVF a differentiated diligence advantage: portfolio companies get direct access to payer operators who can validate product-market fit and unlock commercial contracts.

Founder Preferences

BVF favors founders building products that solve concrete pain points for health plans and their members -- care delivery redesign, plan operations technology, and clinical decision support -- where a warm introduction into the Blue Plan network is a genuine value-add rather than a nice-to-have. The fund is less suited to consumer-only or non-healthcare business models given its strategic mandate.

Geographic Focus

Primarily United States-focused, reflecting the domestic footprint of the Blue Cross Blue Shield system and its member plans.

04Selected Portfolio
Biotech & Life Sciences
Exai Bio·Octave Bioscience·PinkDx·HeartFlow
Enterprise Software
Tango·Nexidia·Owl·Thrive
Fintech & Payments
Origin·Patientco
Healthcare & Digital Health
HealthEdge·Belong Health·Alacura·Bluestone Physician Services·CirrusMD·Drips·eMIDS·Fort Health·Ideal Option·InsightIn Health·Lumeris·Perspectum·PicassoMD·Rula·Sempre Health·SmartData Solutions·Solera Health·Somatus·SonarMD·Daymark Health·AbleTo·ArroHealth·Aspire Health·Bloom Health·CareCentrix·Change Healthcare·Contessa Health·First Dollar·ExactCare Pharmacy·Healthbox·Healthify·Initiate Systems·Limber Health·InVivoLink·naviHealth·Noctrix Health·OncoHealth·Phreesia·Physera·Picwell·pwnhealth·SwipeSense·Verata Health·Waltz Health·Big Health·Nest Health·Humata Health·Onc.ai
Security & Cybersecurity
Prove·ID Experts
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

Participated in Big Health's $23.7M strategic funding round alongside .406 Ventures, AlleyCorp, and CVS Health Ventures to accelerate adoption of FDA-cleared digital treatments for insomnia and anxiety.
INVESTMENT·bhbusiness.com+1
FEB 12, 2026
Co-led Nest Health's Series A round (initially $12.5M, closing above $22.5M) to expand its Medicaid-focused in-home and virtual family primary care model.
INVESTMENT·prnewswire.com+1
AUG 25, 2025
Led Humata Health's $25M investment round, with participation from LRVHealth, Optum Ventures, .406 Ventures, Highmark Ventures, and VentureforGood, to scale AI-driven prior authorization technology.
INVESTMENT·businesswire.com
JUN 20, 2024
Co-led Onc.AI's $6M financing round alongside Accomplice to advance its precision oncology care management platform.
INVESTMENT·businesswire.com
DEC 3, 2020
06Frequent co-investors
LC
Lifeforce Capital
Both backed 3 of the same companies
Aspire Health, HeartFlow, Sempre Health
.V
.406 Ventures Fund
Both backed 2 of the same companies
Humata Health, Big Health
MS
Meridian Street Capital
Both backed 2 of the same companies
Rula, First Dollar
OV
Optum Ventures
Both backed 2 of the same companies
AbleTo, Somatus
SV
SemperVirens Venture Capital
Both backed 2 of the same companies
Rula, Origin
Find the investors for your round→
07Similar Firms
FH
FCA Health Innovations
$2M – $8M · Seed · Series A
→
FC
Flare Capital Partners
$1M – $10M · Seed · Series A
→
MS
Meridian Street Capital
$100K – $5M · Pre-Seed · Seed
→
MV
MedMountain Ventures
$500K – $5M · Pre-Seed · Seed
→
TC
Transformation Capital
$5M – $20M · Series A · Series B
→
Quick Reference
Check Size
$1M – $20M
Stages
Seed · Series A · Series B · Growth
AUM
$800M
Decision
Investment Committee
Location
Chicago, IL
Sector Focus
Biotech & Life SciencesHealthcare & Digital Health
Models
Healthcare ServicesHealthcare TechnologyClinical Sciences
Technology
AI/MLDigital Health Platforms
See all Biotech & Life Sciences investors →See all Healthcare & Digital Health investors →
Visit blueventurefund.com ↗

See how Blue Venture Fund matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Biotech & Life SciencesHealthcare & Digital Health

See how Blue Venture Fund matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched August 28, 2026F4 Research Engine